CN107007832A - A kind of preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position - Google Patents
A kind of preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position Download PDFInfo
- Publication number
- CN107007832A CN107007832A CN201610054517.8A CN201610054517A CN107007832A CN 107007832 A CN107007832 A CN 107007832A CN 201610054517 A CN201610054517 A CN 201610054517A CN 107007832 A CN107007832 A CN 107007832A
- Authority
- CN
- China
- Prior art keywords
- clfa
- staphylococcus aureus
- vaccine
- preparation
- target position
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000191967 Staphylococcus aureus Species 0.000 title claims abstract description 34
- 241000283690 Bos taurus Species 0.000 title claims abstract description 27
- 239000008267 milk Substances 0.000 title claims abstract description 27
- 235000013336 milk Nutrition 0.000 title claims abstract description 27
- 210000004080 milk Anatomy 0.000 title claims abstract description 27
- 229960005486 vaccine Drugs 0.000 title claims abstract description 22
- 208000004396 mastitis Diseases 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 19
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims abstract description 12
- 239000013612 plasmid Substances 0.000 claims abstract description 12
- 238000012408 PCR amplification Methods 0.000 claims abstract description 9
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 9
- 210000002966 serum Anatomy 0.000 claims abstract description 9
- 238000010241 blood sampling Methods 0.000 claims abstract description 8
- 230000029087 digestion Effects 0.000 claims abstract description 7
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 7
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000002671 adjuvant Substances 0.000 claims description 15
- 238000002649 immunization Methods 0.000 claims description 15
- 230000003053 immunization Effects 0.000 claims description 10
- 230000006698 induction Effects 0.000 claims description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 6
- 238000004945 emulsification Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 235000009074 Phytolacca americana Nutrition 0.000 claims description 2
- 240000007643 Phytolacca americana Species 0.000 claims description 2
- 238000012300 Sequence Analysis Methods 0.000 claims description 2
- 101100508919 Arabidopsis thaliana IPT6 gene Proteins 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 4
- 230000004520 agglutination Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 238000011534 incubation Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000010065 bacterial adhesion Effects 0.000 description 2
- 108010056458 bacterial fibronectin-binding proteins Proteins 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 101710198480 Clumping factor A Proteins 0.000 description 1
- 101710198481 Clumping factor B Proteins 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100027287 Serpin H1 Human genes 0.000 description 1
- 108050008290 Serpin H1 Proteins 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 102000036072 fibronectin binding proteins Human genes 0.000 description 1
- 108091010988 fibronectin binding proteins Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940005654 nitrite ion Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- -1 polypropylene Acrylamide Polymers 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a kind of preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA A target position, extract L-form staphylococcus aureus, according to the ClfA gene orders being had been filed on GenBank, separately design sense primer and anti-sense primer, and upstream, with introducing Bam H I and Hind III digestions site respectively in anti-sense primer, recombinant plasmid pET ClfA A are made in primer；Enter performing PCR amplification, recombinant plasmid pET ClfA A are transferred in competent cell BL21 (DE3), induced with IPTG, great expression and purifying are carried out to destination protein；Rabbit is taken, blood sampling obtains serum after being immunized, and is detected；Blood sampling obtains serum after immune programme for children, determines after antibody titer, and staphylococcus aureus mastitis for milk cows vaccine is made.The preparation for the effective staphylococcus aureus agglutination factor albumen (ClfA A) that the present invention is set up, is the vaccine research using ClfA A as target position, and the research to staphylococcus aureus property mastitis for milk cows vaccine provides test basis.
Description
Technical field
The present invention relates to animal gene technical field, specifically a kind of staphylococcus aureus cow breast of ClfA-A target position
The preparation method of scorching vaccine.
Background technology
Mastitis for milk cows (Bovine Mastitis) is the common disease of milk cow, is the inflammation of cow mammary gland tissue, mainly
It is common disease, the frequently-occurring disease of milk cow caused by breast tissue pathogenic infection microorganism.In decades, both at home and abroad for milk cow
Many effort have been made in the preventing and treating of mammitis, but the disease be always perplex China's dairy cultivation development the most serious disease it
One.It makes Lactation of Dairy Cow and Reproductive Performance sustain damage, and not only reduces the output of milk of milk cow, eliminates milk cow, influence breast
Quality causes serious economic loss, and even human health is had influence on when serious.
The first step of S.a μ reus infection is exactly to be colonized in host, and realizes that the premise being colonized is tissue of the bacterium in host
With sticking for cell surface, bacterium has the component that can be attached to tissue surface to turn into adhesin, and S.aureus, which sticks, to be have
Fibrin primary agglutinin A, B (Fibronectin-binding proteins clumping factor A and B, ClfA,
ClfB), fibrin A, B (Fibronectin-binding protein A and B, FnBPA, FnBPB), collagen
Associated proteins (collagen-binding protein Can) and A albumen (protein A), ClfA is Staphylococcus aureus
One of main adhesin of bacterium, can mediate staphylococcus aureus to be incorporated into the cellulose connection proteinogen of cell surface, make
Bacterial adhesion promotes invasion of the cell to host tissue in host cell surface.ClfA be by bacterial adhesion to fibrin and
Decision sex factor on solvable and insoluble fibrin is former.
The content of the invention
It is an object of the invention to provide a kind of preparation side of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position
Method, to solve the problems mentioned in the above background technology.
To achieve the above object, the present invention provides following technical scheme：
A kind of preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position, is comprised the steps of：
1) recombinant plasmid pET-ClfA-A structure
L-form staphylococcus aureus is extracted, according to the ClfA gene orders being had been filed on GenBank, upstream is separately designed and draws
Thing and anti-sense primer, and upstream primer, with introducing Bam HI and Hind III digestions site respectively in anti-sense primer, is made
Recombinant plasmid pET-ClfA-A；
Sense primer P1 sequences such as SEQ ID NO：Shown in 1,
Anti-sense primer P2 sequences such as SEQ ID NO：Shown in 2,
Then performing PCR amplification is entered to recombinant plasmid pET-ClfA-A, pcr amplification product is detected through agarose gel electrophoresis；Through
The positive colony that blue hickie screening and double digestion identification are obtained carries out Sequence analysis；
2) expression product of induction
Above-mentioned recombinant plasmid pET-ClfA-A is transferred in competent cell BL21 (DE3), with final concentration of 0.8-1.2mM's
IPTG (isopropylthiogalactoside) is induced, and takes the expression product of different time sections to carry out SDS-PAGE (polypropylene
Acrylamide gel electrophoresis) detection；
3) great expression of destination protein and purifying
According to SDS-PAGE detect determine optimal induction time and IPTG concentration, to destination protein carry out great expression and
Purifying；
4) screening of animal is immunized
Body weight 2~2.5kg rabbit are chosen, blood sampling obtains serum after being immunized, and is detected；
5) immune programme for children：
First immunisation：On destination protein and immunizing rabbit after Freund's complete adjuvant emulsification, every rabbit injection 650-750 μ g
State destination protein, dorsal sc multi-point injection；
After first immunisation every 15d booster immunizations once, using incomplete Freund's adjuvant as adjuvant, every rabbit 250-350 μ g
Destination protein, the 3rd immune rear 10d blood sampling obtains serum, determines after antibody titer, staphylococcus aureus milk is made
Garget vaccine.
It is used as further scheme of the invention：PCR amplification conditions：94℃5min；94℃30s、62℃45s、72℃1min
30s, 35 circulations；72℃10min.
It is used as further scheme of the invention：Step 2) in IPTG final concentration of 1.0mM.
It is used as further scheme of the invention：First immunisation：Destination protein and immunizing rabbit after Freund's complete adjuvant emulsification, often
Rabbit injects 700 μ g destination proteins.
It is used as further scheme of the invention：After first immunisation every 15d booster immunizations once, using incomplete Freund's adjuvant as
Adjuvant, every μ g destination protein of rabbit 300.
Staphylococcus aureus mastitis for milk cows vaccine is made according to the above method.
Compared with prior art, the beneficial effects of the invention are as follows：
The preparation for the effective staphylococcus aureus agglutination factor albumen (ClfA-A) that the present invention is set up, is with ClfA-A
For the vaccine research of target position, the research to staphylococcus aureus property mastitis for milk cows vaccine provides test basis.
Brief description of the drawings
Fig. 1 is the amplification figure of ClfA-A areas gene, M：DNA molecular quality standard, 1：PCR primer；
Fig. 2 is the SDS-PAGE analysis charts of destination protein, M：Protein standard, 1：Under IPTG inductions
Expression of the pET-32a-ClfA-A in BL21,2：Expression of the pET-32a-ClfA-A in BL21 when being induced without IPTG,
3：Empty carrier under IPTG inductions.
Embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described, shown
So, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
In the embodiment of the present invention, a kind of preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position,
Concrete operation step：
1st, recombinant plasmid pET-ClfA-A structure
According to bibliography extraction L-form staphylococcus aureus, the ClfA gene orders (Z18852) that GenBank is logged in,
Upstream and downstream primer is designed with Primer5.0,
Sense primer P1 sequences：5’-CGCGGATCCGTAGCTGCAGATGCACC-3’；
Anti-sense primer P2 sequences：5’-CCCAAGCTTCTCATCAGGTTGTTCAGG-3’。
Its directed cloning, Bam HI and Hind III digestions site (underscore part) is introduced in upstream and downstream respectively for convenience,
PCR amplification conditions：94℃5min；94 DEG C of 30s, 62 DEG C of 45s, 72 DEG C of 1min30s, 35 circulations；72 DEG C of 10min,
Pcr amplification product is detected through agarose gel electrophoresis.Screened through blue hickie and double digestion identifies that obtained positive colony carries out sequence
Row determine analysis.
Expressed after sequencing correctly.(see Fig. 1)
2nd, the expression product of induction
The recombinant plasmid of above-mentioned structure is transferred in competent cell BL21 (DE3), carried out with final concentration of 1.0mM IPTG
Induction, takes the expression product of different time sections to carry out SDS-PAGE detections.
3rd, the great expression of albumen and purifying
Identified, destination protein exists with soluble form, expands after culture, the optimal induction time determined according to preliminary experiment
With IPTG concentration, great expression and purifying are carried out.(see Fig. 2)
4th, the screening of animal is immunized
Body weight 2~2.5kg rabbit are chosen, blood sampling obtains serum after being immunized, and is detected.
5th, immune programme for children：
First immunisation：Destination protein and immunizing rabbit after Freund's complete adjuvant emulsification, every 700 above-mentioned recombinant proteins of μ g,
Dorsal sc multi-point injection.
After first immunisation every 15d booster immunizations once, using incomplete Freund's adjuvant as adjuvant, every μ g egg of rabbit 300
In vain, the 3rd immune rear 10d blood sampling obtains serum, determines antibody titer,
6th, expression product ELISA is detected
100 μ L BFGs (4 μ g/mL) are coated with 96 hole elisa Plates, and 4 DEG C overnight；200 μ L gelatin (1g/L)
Closing, 37 DEG C of incubation 2h；100 μ L destination protein (5 μ g/mL) is added, to be not added with the hole of destination protein as control,
37 DEG C of incubation 2h；Add homemade primary antibody (rabbit anteserum of 1: 4000 dilution) 100 μ L, 37 DEG C of incubation 2h；Add sheep
ELIAS secondary antibody (1: 1000 dilution) 100 the μ L, 37 DEG C of incubation 2h of anti-rabbit；Add the μ L of nitrite ion 100,37 DEG C of incubations
10~30min；Add the μ L of terminate liquid 100；Determine OD values at 490nm.
7th, antibody anti-adhesion ability is detected
The μ L of 4 μ g/mL BFGs 100 are coated with 96 hole elisa Plates, and 4 DEG C are overnight, after TBST buffer solutions are washed 2 times,
Softly pat dry；Add the closing of 100 μ L gelatin (1g/L), 37 DEG C of incubation 2h；The staphylococcus aureus of exponential phase,
Add isometric self-control primary antibody, 37 DEG C of incubation 30min；The 1/2 of hole count is selected to add through making serum by oneself in the enzyme mark hole being coated with
The μ L of staphylococcus aureus 100 of incubation, remaining 1/2 adds the golden yellow grape of the exponential phase without sera incubation
Coccus, 37 DEG C of incubation 2h；After TBST buffer solutions are washed 3 times, softly pat dry；250mL/L formaldehyde is added, room temperature is placed
10~30min；After TBST buffer solutions are washed 3 times, softly pat dry；Add the washing of violet staining 30min, TBST buffer solution
After 3 times, softly pat dry；Ethanol decolorization 20min is added, crystal violet all abjections are made as far as possible；Determine OD values at 583nm.
8th, result
The detection of antibody Adhering capacity shows, adds the OD583 in the enzyme mark hole of the staphylococcus aureus without sera incubation
The OD583 of (1.031 ± 0.23, n=13) apparently higher than the enzyme mark hole for adding the staphylococcus aureus through sera incubation
(0.693 ± 0.23, n=13), the i.e. staphylococcus aureus without sera incubation are adhered to the energy on BFG
Power is stronger, and the ability that the staphylococcus aureus after sera incubation is adhered to BFG is decreased obviously.
Therefore, by the above method, the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position can be prepared, is
The preventing and treating of mastitis for milk cows provides the foundation from now on.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, and do not carrying on the back
In the case of spirit or essential attributes from the present invention, the present invention can be realized in other specific forms.Therefore, no matter from
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each embodiment is only included
One independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should be by
Specification is as an entirety, and the technical solutions in the various embodiments may also be suitably combined, and forming those skilled in the art can
With the other embodiment of understanding.
Claims (6)
1. a kind of preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position, it is characterised in that by
Following steps are constituted：
1) recombinant plasmid pET-ClfA-A structure
L-form staphylococcus aureus is extracted, according to the ClfA gene orders being had been filed on GenBank, upstream is separately designed and draws
Thing and anti-sense primer, and upstream primer, with introducing Bam H I and Hind III digestions site respectively in anti-sense primer, is made
Recombinant plasmid pET-ClfA-A；
Sense primer P1 sequences such as SEQ ID NO：Shown in 1,
Anti-sense primer P2 sequences such as SEQ ID NO：Shown in 2,
Then performing PCR amplification is entered to recombinant plasmid pET-ClfA-A, pcr amplification product is detected through agarose gel electrophoresis；Through
The positive colony that blue hickie screening and double digestion identification are obtained carries out Sequence analysis；
2) expression product of induction
Above-mentioned recombinant plasmid pET-ClfA-A is transferred in competent cell BL21 (DE3), with final concentration of 0.8-1.2mM's
IPTG is induced, and takes the expression product of different time sections to carry out SDS-PAGE detections；
3) great expression of destination protein and purifying
According to SDS-PAGE detect determine optimal induction time and IPTG concentration, to destination protein carry out great expression and
Purifying；
4) screening of animal is immunized
Body weight 2~2.5kg rabbit are chosen, blood sampling obtains serum after being immunized, and is detected；
5) immune programme for children：
First immunisation：On destination protein and immunizing rabbit after Freund's complete adjuvant emulsification, every rabbit injection 650-750 μ g
State destination protein, dorsal sc multi-point injection；
After first immunisation every 15d booster immunizations once, using incomplete Freund's adjuvant as adjuvant, every rabbit 250-350 μ g
Destination protein, the 3rd immune rear 10d blood sampling obtains serum, determines after antibody titer, staphylococcus aureus milk is made
Garget vaccine.
2. the preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position according to claim 1,
Characterized in that, PCR amplification conditions：94℃5min；94 DEG C of 30s, 62 DEG C of 45s, 72 DEG C of 1min 30s, 35 are followed
Ring；72℃10min.
3. the preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position according to claim 1,
Characterized in that, step 2) in IPT6 final concentration of 1.0mM.
4. the preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position according to claim 1,
Characterized in that, first immunisation：Destination protein injects 700 μ g with immunizing rabbit after Freund's complete adjuvant emulsification, every rabbit
Destination protein.
5. the preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position according to claim 1,
Characterized in that, after first immunisation every 15d booster immunizations once, using incomplete Freund's adjuvant as adjuvant, every rabbit 300
μ g destination proteins.
6. staphylococcus aureus mastitis for milk cows vaccine is made according to any described preparation methods of claim 1-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610054517.8A CN107007832A (en) | 2016-01-28 | 2016-01-28 | A kind of preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610054517.8A CN107007832A (en) | 2016-01-28 | 2016-01-28 | A kind of preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107007832A true CN107007832A (en) | 2017-08-04 |
Family
ID=59438949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610054517.8A Pending CN107007832A (en) | 2016-01-28 | 2016-01-28 | A kind of preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107007832A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1109577A4 (en) * | 1998-08-31 | 2002-03-13 | Inhibitex Inc | VACCINES WITH MULTIPLE CONSTITUENTS |
| CN102847172A (en) * | 2012-10-17 | 2013-01-02 | 西北农林科技大学 | Preparation method of genetic engineering vaccine for preventing staphylococcus caprae mastitis application |
-
2016
- 2016-01-28 CN CN201610054517.8A patent/CN107007832A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1109577A4 (en) * | 1998-08-31 | 2002-03-13 | Inhibitex Inc | VACCINES WITH MULTIPLE CONSTITUENTS |
| CN102847172A (en) * | 2012-10-17 | 2013-01-02 | 西北农林科技大学 | Preparation method of genetic engineering vaccine for preventing staphylococcus caprae mastitis application |
Non-Patent Citations (2)
| Title |
|---|
| 姜晓娟: "奶牛乳腺炎金黄色葡萄球菌凝聚因子A A区基因的克隆表达", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
| 姜晓娟等: "金黄色葡萄球菌凝聚因子 A区基因的克隆表达及表达产物的免疫学特性", 《中国兽医科学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kitching et al. | Global FMD control—is it an option? | |
| CN103172749B (en) | Preparation of African swine fever protein engineering vaccine | |
| CN103539842A (en) | Recombinant protein coded by grass carp reovirus (GCRV) type-II S10 gene, polyclonal antibody prepared from recombinant protein and application of recombinant protein | |
| CN102772794A (en) | Application of brucellosis A19 molecular marking vaccine and immunological identification thereof | |
| CN103045635A (en) | Expression process of coat protein gene of prunus necrotic ring spot virus (PNRSV), antiserum and kit | |
| CN111825764B (en) | Brucella canicola monoclonal antibody and application thereof | |
| CN102240399B (en) | Application of siniperca chuatsi ISKNV (Infectious Spleen and Kidney Necrosis Virus) ORF093 protein | |
| CN102181457B (en) | Clostridium difficile exotoxin B amino-terminal gene sequence with optimized codon and nucleic vaccine of clostridium difficile exotoxin B | |
| CN103421832B (en) | Comprise yolk antibody and the preparation and application of florfenicol Drug Resistance Gene Associated Proteins | |
| CN102816246A (en) | Human cytomegalo virus immunogen fusion protein as well as preparation method and usage thereof | |
| CN104694457A (en) | Cell strain for producing goatpox vaccine | |
| CN104498438A (en) | West nile virus monoclonal antibody and kit | |
| CN103060250A (en) | Genetically engineered bacteria strain expressing porcine transmissible gastroenteritis virus | |
| CN102604993B (en) | Immunologic adjuvant-Helicobacter pylori antigen fused protein oral vaccine and preparation method thereof | |
| CN107007832A (en) | A kind of preparation method of the staphylococcus aureus mastitis for milk cows vaccine of ClfA-A target position | |
| CN104511015B (en) | A kind of vaccine combination and preparation method and application | |
| CN118388664B (en) | Haemophilus parasuis fusion antigen and application thereof | |
| CN103789333B (en) | A kind of oral recombination fusion protein TAT-MAP30 and preparation method and application | |
| CN101020894B (en) | Avirulent type-2 pig streptococcus strain and its prepn and application | |
| Hajikolaei et al. | Seroprevalence of leptospiral infection in buffalo (Bubalus bubalis) | |
| CN103233017A (en) | Gametophyte antigen gam22 gene of Eimeria necatrix and application of gene | |
| CN103275219B (en) | Schmallenberg virus nucleocapsid protein monoclonal antibody, and preparation method thereof | |
| CN109856397B (en) | Colloidal gold detection card for rapidly detecting rabbit plague virus and preparation method thereof | |
| CN109608541B (en) | Yolk antibody for resisting swine enterotoxigenic escherichia coli and preparation method thereof | |
| Singh et al. | Therapeutic management of clinical Bovine Johne’s disease using goat based ‘indigenous vaccine’in native Hariana Cattle: case reports |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170804 |